Glaukos Revenue Growth Rates (GKOS), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Glaukos Corp  (NYSE: GKOS)
 

GKOS's Revenue Growth by Quarter and Year

Glaukos's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/GKOS/growth
https://api.csimarket.com/api/v1/companies/GKOS/fundamentals
https://api.csimarket.com/api/v1/companies/GKOS/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
GKOS Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 211.03
2nd Quarter June 185.61
1st Quarter March 150.23
FY 546.87

GKOSs Annual Revenue
Glaukos's Revenue in the fiscal year 2025 $ 393.76 millions
Glaukos's Revenue in the fiscal year 2024 $ 383.45 millions
Glaukos's Revenue in the fiscal year 2023 $ 314.14 millions
Glaukos's Revenue in the fiscal year 2022 $ 282.86 millions
Glaukos's Revenue in the fiscal year 2021 $ 294.01 millions




GKOS Revenue third quarter 2026 Y/Y Growth Comment
Glaukos Corp achieved in the third quarter 2026, above Company average Revenue rise of 59.02% year on year, to $ 211.03 millions.

Looking into third quarter 2026 results within Medical Equipment & Supplies industry 27 other companies have achieved higher Revenue growth. While Glaukos Corp' s Revenue jump of 59.02% ranks overall at the positon no. 459 in the third quarter 2026.


GKOS Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 59.02 %
2nd Quarter June 50.63 %
1st Quarter March 41.26 %
FY   -

Financial Statements
Glaukos's third quarter 2026 Revenue $ 211.03 millions GKOS's Income Statement
Glaukos's third quarter 2025 Revenue $ 132.71 millions Quarterly GKOS's Income Statement


GKOS Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 13.7 %
2nd Quarter June 23.55 %
1st Quarter March 377.22 %
FY (Year on Year)   -


Back to GKOS Growth rate Comparisons >> Back to GKOS Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #28
Healthcare Sector #118
Overall #459

Revenue Y/Y Growth Statistics
High Average Low
147.46 % 26.74 % -70.54 %
(Mar 31 2017)   (Mar 31 2021)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #28
Healthcare Sector #118
Overall #459
Revenue Y/Y Growth Statistics
High Average Low
147.46 % 26.74 % -70.54 %
(Mar 31 2017)   (Mar 31 2021)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Glaukos's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
377.18 % 13.87 % -76.28 %
(Mar 31 2026)  


GKOS's III. Quarter Q/Q Revenue Comment
Glaukos Corp achieved in the III. Quarter 2026 below company average Revenue rise of 13.7% quarter on quarter, to $ 211.03 millions.

III. Quarter 2026 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the 7.7% in the III. Quarter a year ago.

Within Medical Equipment & Supplies industry 22 other companies have achieved higher Revenue quarter on quarter growth. While Glaukos's Revenue growth quarter on quarter, overall rank is 443.


Revenue Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #23
Healthcare Sector #94
Overall #443
Revenue Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #23
Healthcare Sector #94
Overall #443
Revenue Q/Q Growth Statistics
High Average Low
377.18 % 13.87 % -76.28 %
(Mar 31 2026)  


GKOS's III. Quarter Q/Q Revenue Comment
Glaukos Corp achieved in the III. Quarter 2026 below company average Revenue rise of 13.7% quarter on quarter, to $ 211.03 millions.

III. Quarter 2026 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the 7.7% in the III. Quarter a year ago.

Within Medical Equipment & Supplies industry 22 other companies have achieved higher Revenue quarter on quarter growth. While Glaukos's Revenue growth quarter on quarter, overall rank is 443.


Glaukos's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2026)		 12 Months Ending (Jun 30 2026) 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025)
Cumulative Revenue 12 Months Ending $ 578.35
Y / Y Revenue Growth (TTM) 23.28 %
Year on Year Revenue Growth Overall Ranking # 630
Seqeuential Revenue Change (TTM) 15.66 %
Seq. Revenue Growth (TTM) Overall Ranking # 1892


Cumulative Revenue growth Comment
Glaukos saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 23.28% year on year, to $ 578 millions if the fiscal year would have ended in Sep 30 2026.
Glaukos's trailing twelve months Revenue growth was higher than company's average 22.55% and higher than 15.61% growth in Jun 30 2026.
But from twelve months ended Jun 30 2026 rise was beneth at 15.66 % from $500.03 millions achieved in the period from Jun 30 2026 to Sep 30 2025.
We witness drop-off happening, more obvious observing the usual Q/Q TTM historic rise that is stronger at42.7%.

In the Healthcare sector 133 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 153 to 630.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 107
Healthcare Sector # 134
Overall # 630

Revenue TTM Y/Y Growth Statistics
High Average Low
65.13 %
 22.55 %
-5.07 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 107
Sector # 294
S&P 500 # 1892
Cumulative Revenue growth Comment
Glaukos saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 23.28% year on year, to $ 578 millions if the fiscal year would have ended in Sep 30 2026.
Glaukos's trailing twelve months Revenue growth was higher than company's average 22.55% and higher than 15.61% growth in Jun 30 2026.
But from twelve months ended Jun 30 2026 rise was beneth at 15.66 % from $500.03 millions achieved in the period from Jun 30 2026 to Sep 30 2025.
We witness drop-off happening, more obvious observing the usual Q/Q TTM historic rise that is stronger at42.7%.
The momentum is even more impressive from twelve months ended Jun 30 2026 exhibited at 15.66 % increase from $500.03 millions in the period from Jun 30 2026 to Sep 30 2025.

In the Healthcare sector 133 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 153 to 630.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 107
Healthcare Sector # 134
Overall # 630

Revenue TTM Y/Y Growth Statistics
High Average Low
65.13 %
22.55 %
-5.07 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 107
Sector # 294
S&P 500 # 1892




Other Revenue Growth
Medical Equipment & Supplies Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
GKOS's Revenue Growth Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue rise for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Keros Therapeutics Inc 88.77%$ 88.766 millions
Profound Medical Corp 85.86%$ 85.857 millions
Syndax Pharmaceuticals Inc 81.59%$ 81.592 millions
Iovance Biotherapeutics inc 80.07%$ 80.074 millions
Rhythm Pharmaceuticals Inc 79.59%$ 79.594 millions
Omniab Inc 78.34%$ 78.339 millions
Aclarion Inc 78.09%$ 78.086 millions
Personalis Inc 76.59%$ 76.585 millions
Delcath Systems Inc 76.05%$ 76.047 millions
Mobia Medical Inc 73.28%$ 73.280 millions
Wave Life Sciences Ltd 72.95%$ 72.950 millions
Igc Pharma Inc 71.73%$ 71.728 millions
Phathom Pharmaceuticals Inc 71.14%$ 71.142 millions
Ptc Therapeutics inc 69.57%$ 69.571 millions
Seres Therapeutics Inc 68.95%$ 68.946 millions
Alamar Biosciences Inc 68.46%$ 68.458 millions
Corcept Therapeutics Inc63.97%$ 63.974 millions
Tarsus Pharmaceuticals Inc 63.92%$ 63.921 millions
Tg Therapeutics Inc 60.74%$ 60.743 millions
Glaukos Corp59.02%$ 59.021 millions
X4 Pharmaceuticals Inc58.64%$ 58.640 millions
Kiniksa Pharmaceuticals International Plc58.12%$ 58.121 millions
Envoy Medical Inc 57.14%$ 57.143 millions
Butterfly Network Inc 53.45%$ 53.453 millions
Avita Medical Inc 53.05%$ 53.054 millions
Immunitybio inc 52.34%$ 52.338 millions
Axsome Therapeutics Inc 51.87%$ 51.873 millions
Innovative Eyewear Inc 51.12%$ 51.123 millions
Strata Critical Medical Inc 50.27%$ 50.272 millions
Madrigal Pharmaceuticals Inc 50.13%$ 50.127 millions


About Glaukos Revenue Growth Rates (GKOS), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Glaukos Corp (CIK 1192448).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001193125-26-436400
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Glaukos Corp’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.